drugset
drugset / Trial / NCT04941378

OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT04941378 ↗

Phase 1 Withdrawn Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelOther

Summary

The primary objective of the study is to compare the performance of different camera imaging systems in assessing the positive predictive values and sensitivity of OTL38 to detect folate positive ovarian cancer cancers using the gold standard of pathologic review.

Timeline

Start
2022-05-28
Primary completion
2022-05-28
Completion
2022-05-28

Outcome

Outcome not reported

Stopped: “Due to sponsor request”

Drugs

EvaluationDrugModalityDoseRoute
Subject pafolacianine Diagnostic / imaging agent 0.025 mg/kg Intravenous

Indications

ovarian cancer